Sermorelin vs CJC-1295: how the two GHRH analogs differ
Two peptides aimed at the same target — but with very different timing dials.
TL;DR
- Sermorelin and CJC-1295 both act on the same pituitary signal, but their durations are very different.
- Sermorelin gives a short, natural-pulse-shaped nudge; CJC-1295 with DAC gives a sustained elevation over days.
- Choice depends on the goal: preserve pulses, simplify dosing, or rebuild a depleted axis.
What it is
Both compounds are GHRH analogs (in plain English: man-made versions of the brain's own growth-hormone-releasing hormone). Picture a doorbell wired to the pituitary: GHRH presses the bell, GH comes out. Sermorelin is the bell-press itself — it lasts about 10 minutes in the bloodstream. CJC-1295 modifies the same signal so it lasts longer. The DAC ("drug affinity complex") version binds to albumin and lasts roughly a week.
How it works
Both ring the same bell but with very different timing. Sermorelin produces a short, pulse-shaped GH release that mirrors the body's natural overnight wave. CJC-1295 without DAC lasts about 30 minutes — still pulsatile. CJC-1295 with DAC produces a flatter, sustained GH elevation across days. The trade-off is rhythm versus convenience: pulses preserve the body's negative-feedback loops, sustained signal is easier to dose (Goth et al., J Clin Endocrinol Metab, 2005).
Who asks about it
People come to this comparison after reading about one of the two and wondering whether the other fits better. Some are switching because of injection-frequency frustration. Others are deciding between a more natural pulse pattern and a simpler weekly shot.
What the research says
Sermorelin has been studied in adults with adult-onset GH decline; trials show short pulse-shaped GH rises and modest IGF-1 increases over 12–16 weeks. CJC-1295 with DAC was studied in healthy adults and produced sustained GH and IGF-1 elevations for about 6 days after a single dose (Teichman et al., J Clin Endocrinol Metab, 2005). Side-effect profiles are similar — injection-site reactions, transient flushing, fluid retention in roughly 1 in 10 patients. Long-term human safety data is limited for both.
What to know before considering it
Both require a prescription and are compounded by 503A pharmacies. Sermorelin is usually nightly; CJC-1295 with DAC is usually once or twice weekly. Both are paired most often with ipamorelin to add a second, complementary pituitary signal. Active cancer, untreated retinopathy, and pregnancy are exclusions for both.
The Halftime POV
We tend to favor short, pulse-shaped signals — sermorelin or CJC-1295 without DAC — for first-time GH-peptide users because they preserve the body's rhythm and let labs reflect the real response. CJC-1295 with DAC is a reasonable option later, once a baseline is established and a clinician decides simpler dosing is the right trade.
Related reading:
- Sermorelin explained: the GHRH analog primer
- CJC-1295: what it is and how it works
- CJC-1295 with DAC vs without DAC
- CJC-1295 + ipamorelin: the most common GH peptide combination
FAQ
Q: What is the main difference between sermorelin and CJC-1295? A: Sermorelin is a short-acting GHRH analog — a minutes-long signal. CJC-1295 with DAC is a long-acting version — a days-long signal. CJC-1295 without DAC sits in between.
Q: Which one preserves natural growth hormone pulsing better? A: Sermorelin and CJC-1295 without DAC preserve the body's pulsatile growth hormone rhythm. CJC-1295 with DAC produces a flatter, sustained elevation — closer to a continuous bleed than a pulse.
Q: Are sermorelin and CJC-1295 FDA-approved? A: Sermorelin was once an FDA-approved drug (brand Geref) for pediatric GH deficiency but was withdrawn. Both are now available through 503A compounding pharmacies and the compounded versions are not FDA-approved.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Sustained GH and IGF-1 response to CJC-1295 — J Clin Endocrinol Metab, 2005
- GHRH analog pharmacology and pulsatility — J Clin Endocrinol Metab, 2005
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is the main difference between sermorelin and CJC-1295?
Sermorelin is a short-acting GHRH analog — minutes-long signal. CJC-1295 with DAC is a long-acting version — days-long signal. CJC-1295 without DAC sits in between.
Which one preserves natural growth hormone pulsing better?
Sermorelin and CJC-1295 without DAC preserve the body's pulsatile growth hormone rhythm. CJC-1295 with DAC produces a flatter, sustained elevation — closer to a continuous bleed than a pulse.
Are sermorelin and CJC-1295 FDA-approved?
Sermorelin was once an FDA-approved drug (brand Geref) for pediatric GH deficiency but was withdrawn. Both are now available through 503A compounding pharmacies and the compounded versions are not FDA-approved.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.